Ipamorelin vs CJC-1295 No-DAC: GHRP and GHRH explained

Ipamorelin and CJC-1295 no-DAC (modified GRF 1-29) are often discussed together because they are the most popular GH peptide stack in bodybuilding. But they are not alternatives to each other: they act on different receptors and serve different roles in the GH release cascade.

Ipamorelin is a GHRP (growth hormone-releasing peptide) that activates the ghrelin receptor (GHS-R1a) in the pituitary. It directly triggers GH release from somatotroph cells. It is highly selective: unlike older GHRPs (GHRP-2, GHRP-6), it does not stimulate cortisol, ACTH, or prolactin release even at doses 200 times the effective GH dose (Raun et al., 1998, PMID 9849822).

CJC-1295 no-DAC is a GHRH analog (GHRH receptor agonist) that primes somatotrophs and amplifies the GH pulse when a GHRP triggers release. With a half-life of approximately 30 minutes, it produces a discrete pulse without the sustained pituitary stimulation of DAC-modified CJC-1295.

Together, ipamorelin (the trigger) and CJC-1295 no-DAC (the amplifier) produce a GH pulse substantially larger than either compound alone. This is the mechanistic basis for the stack's popularity.

Receptor class: Ipamorelin targets GHS-R1a (ghrelin receptor). CJC-1295 no-DAC targets the GHRH receptor. These are different receptors on the same somatotroph cells, activated by different endogenous signals (ghrelin vs. GHRH). This is why they synergise rather than compete.

Role in GH release: Ipamorelin is the trigger: it directly initiates GH release. CJC-1295 no-DAC is the priming agent: it sensitises the somatotroph and increases the amplitude of the GH response when ipamorelin fires. Using CJC-1295 no-DAC alone relies on endogenous ghrelin for the trigger, which is a submaximal and variable signal.

Selectivity profile: Ipamorelin's selectivity for GHS-R1a is exceptional; it does not affect cortisol, prolactin, LH, FSH, or TSH. CJC-1295 no-DAC, as a GHRH class compound, may contribute to the T4-to-T3 conversion acceleration associated with GHRH analogs (documented for sermorelin; the same class risk applies). Baseline thyroid function testing is prudent.

Can you use one without the other: Yes. Ipamorelin alone produces meaningful pulsatile GH elevation and IGF-1 response. CJC-1295 no-DAC alone produces a more modest signal because it depends on endogenous ghrelin for the trigger. In practice, ipamorelin is the more valuable solo compound; CJC-1295 no-DAC alone is rarely used without a GHRP.

Use ipamorelin alone when:

• You want pulsatile GH elevation with the simplest protocol
• You are new to GH peptides and want to assess your response to a single compound
• Cortisol or prolactin sensitivity makes you prefer a compound with documented hormonal selectivity
• Budget constraints require choosing one compound

Use CJC-1295 no-DAC alone when:

• Rarely recommended as the primary compound; it is best used as an amplifier alongside a GHRP
• If trialing GHRH-class compounds to understand pituitary response before adding a GHRP

Use both together (recommended) when:

• You want to maximise pulsatile IGF-1 elevation without continuous GH stimulation
• You want to close the IGF-1 gap with MK-677 while preserving metabolic safety
• You are building a comprehensive GH optimization protocol with good monitoring in place
• Standard injection protocol: 100 mcg CJC-1295 no-DAC + 200-300 mcg ipamorelin per injection, pre-bed and/or morning fasted